SCMI set for launch in September 2018
In 2017, the Scottish Consortium for Macromolecular Imaging successfully led a bid to secure more than £5 million of funding to create an innovative structural biology centre in Scotland.
With Dr David Bhella at the helm as Director, the new Scottish Centre for Macromolecular Imaging (SCMI) will be housed here at the CVR and is the result of a collaboration between researchers from Glasgow, Edinburgh, Dundee and St Andrews.
This investment is part of £11.3m in government funding, awarded through the Medical Research Council (MRC) to boost structural and cell biology research, and was announced by Jo Johnson, Minister of State for Universities, Science, Research and Innovation.
Additional support will come from the Scottish Funding Council, Scottish Universities Life Sciences Alliance (SULSA) and the Beatson Institute for Cancer Research. A further charitable donation has been made by the M J M Smith Trust for the supply of essential computer equipment.
Supporting Life Sciences through cutting-edge technology
The funding will support the purchase of a cutting-edge electron microscope, which will be used to image biological molecules at the atomic level.
Structural biology involves determining the 3D architecture of proteins and other biological components in order to provide crucial insights into important processes in human health and disease. Cryogenic transmission electron microscopy is revolutionising the field of structural biology. The Scottish Macromolecular Imaging Centre is a tremendous opportunity not only for the CVR but also for Life Scientists throughout Scotland. The new facility will place the CVR and the University of Glasgow right at the centre of vital structural biology research by offering a world-class capability. The new technology will help us investigate key processes in, for example, infection and cancer biology.
Installation of the new centre is currently underway with the new service scheduled for launch in September 2018. The technology will be used to support vital research into diseases posing the greatest threat to human and animal health. It will provide greater capabilities in areas such as vaccine development, cancer research, and drug design and discovery.